§ 356e. Drug shortage list
424 words·~2 min read·
/usc/title-21/section-356eA research copy — for the controlling text, always check the official state or federal source. Not legal advice.
(a)Establishment The Secretary shall maintain an up-to-date list of drugs that are determined by the Secretary to be in shortage in the United States.
(b)Contents For each drug on such list, the Secretary shall include the following information:
(1)The name of the drug in shortage, including the National Drug Code number for such drug.
(2)The name of each manufacturer of such drug.
(3)The reason for the shortage, as determined by the Secretary, selecting from the following categories:
(A)Requirements related to complying with good manufacturing practices.
(B)Regulatory delay.
(C)Shortage of an active ingredient.
(D)Shortage of an inactive ingredient component.
(E)Discontinuance of the manufacture of the drug.
(F)Delay in shipping of the drug.
(G)Demand increase for the drug.
(4)The estimated duration of the shortage as determined by the Secretary.
(c)Public availability
(1)In general Subject to paragraphs
(2)and (3), the Secretary shall make the information in such list publicly available.
(2)Trade secrets and confidential information Nothing in this section alters or amends section 1905 of title 18 or section 552(b)(4) of title 5.
(3)Public health exception The Secretary may choose not to make information collected under this section publicly available under paragraph
(1)or section 356c(c) of this title if the Secretary determines that disclosure of such information would adversely affect the public health (such as by increasing the possibility of hoarding or other disruption of the availability of drug products to patients).
(d)Interagency notification Not later than 180 days after March 27, 2020, and every 90 days thereafter, the Secretary shall transmit a report regarding the drugs of the current drug shortage list under this section to the Administrator of the Centers for Medicare & Medicaid Services.
(June 25, 1938, ch. 675, § 506E, as added Pub. L. 112–144, title X, § 1004, July 9, 2012, 126 Stat. 1104; amended Pub. L. 114–255, div. A, title III, § 3101(a)(2)(G), Dec. 13, 2016, 130 Stat. 1153; Pub. L. 116–136, div. A, title III, § 3112(c), Mar. 27, 2020, 134 Stat. 362.)
Connections123 cite this · traces to 5
Cited by 123 sections · top 60
U.S. Code
- § 355New drugs
- § 381Imports and exports
- § 374Inspection
- § 826Production quotas for controlled substances
- § 353bOutsourcing facilities
- § 356cDiscontinuance or interruption in the production of life-saving drugs
- § 356fHospital repackaging of drugs in shortage
- § 356dCoordination; task force and strategic plan
- § 356lAdvanced manufacturing technologies designation program
public-private-law
statutes-at-large
- Public Law 116–136To amend the Internal Revenue Code of 1986 to repeal the excise tax on high cost employer-sponsored health coverage
- Public Law 112–144To amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs and medical devices, to establish user-fee programs for generic drugs and biosimilars, and for other purposes
- Public Law 114–255To accelerate the discovery, development, and delivery of 21st century cures, and for other purposes
- Public Law 116–94Making further consolidated appropriations for the fiscal year ending September 30, 2020, and for other purposes
- Public Law 117–328Making consolidated appropriations for the fiscal year ending September 30, 2023, and for providing emergency assistance for the situation in Ukraine, and for other purposes
- Public Law 115–52To amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products, and for other purposes
register
- NoticesNotice
- NoticesNotice
- NoticesNotice
- NoticesNotice
- NoticesNotice
- NoticesNotice
- NoticesNotice; revised request for nominations
- NoticesNotice of availability
- NoticesNotice
- NoticesNotice
- Proposed RulesNotification; request for nominations
- NoticesNotice
- NoticesNotice
- NoticesNotice
- NoticesNotice
- NoticesNotice of availability
- NoticesNotice
- NoticesRequest for information
- Rules and RegulationsNotice
- NoticesNotice
- NoticesNotice
- Proposed RulesFinal rule
- NoticesNotice of availability; establishment of public docket
- Rules and RegulationsNotice
- NoticesNotice of availability
- Proposed RulesProposed rule; request for comments
- NoticesNotice
- NoticesNotice
- NoticesNotice of availability
- NoticesNotice
- NoticesNotice
- NoticesNotice
- NoticesNotice of availability
- NoticesFinal order
- NoticesNotice
- Rules and RegulationsFinal rule
Traces to 5 documents
U.S. Code
5 references not yet in our index
- June 25, 1938, ch. 675, § 506E
- Pub. L. 112–144, title X, § 1004
- 126 Stat. 1104
- 130 Stat. 1153
- 134 Stat. 362
Citation graph
cites case law
§ 356e
Drug shortage list
Bills×53
Fed. Reg.×37
U.S.C.×15
Stat.×7
Pub. L.×6
Stat. Comp.×5
ActJune 25, 1938, ch. 675, § 506E
Pub. L.Pub. L. 112–144, title X, § 1004
Stat.126 Stat. 1104
Stat.130 Stat. 1153
Stat.134 Stat. 362
Cites 10Cited by 123 across 6 sources